升糖素市场规模、份额、成长分析(按适应症、给药途径、配方、最终用户和地区)—2025 年至 2032 年产业预测
市场调查报告书
商品编码
1801972

升糖素市场规模、份额、成长分析(按适应症、给药途径、配方、最终用户和地区)—2025 年至 2032 年产业预测

Glucagon Market Size, Share, and Growth Analysis, By Indication (Hypoglycemia, Diabetic Ketoacidosis), By Route of Administration (Intravenous, Subcutaneous), By Formulation, By End-User, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 185 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2023 年全球升糖素市场规模为 6.08 亿美元,预计将从 2024 年的 6.4448 亿美元增长到 2032 年的 10.272 亿美元,预测期内(2025-2032 年)的复合年增长率为 6.0%。

由于糖尿病盛行率上升、紧急医疗治疗的普及以及严重低血糖管理意识的不断增强,全球升糖素市场正经历强劲增长。随着医疗保健系统优先考虑可靠的治疗方案,对有效低血糖治疗的需求正在飙升。紧急注射剂和鼻腔内製剂的进步正在改善患者的治疗效果并提高市场渗透率。对医护人员和患者进行低血糖发作紧急应变的教育,进一步刺激了需求。此外,药物输送系统技术的不断创新和政府的优惠医疗政策也在推动市场扩张。然而,治疗成本高、低收入地区认知度有限、监管障碍以及对低温运输物流的依赖等挑战,持续影响市场策略与区域发展。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二次资料和一次资料方法
  • 市场规模预测
  • 市场假设与约束

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分机会分析

市场动态与展望

  • 市场概览
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数(2024年)
  • PESTEL分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究

升糖素市场规模(依适应症及复合年增长率)(2025-2032 年)

  • 市场概览
  • 低血糖
  • 糖尿病酮酸症
  • 代谢疾病检测

升糖素市场规模(依给药途径及复合年增长率) (2025-2032)

  • 市场概览
  • 静脉
  • 皮下
  • 肌肉注射

升糖素市场规模(依配方及复合年增长率)(2025-2032 年)

  • 市场概览
  • 注射套件
  • 液体稳定性自动注射器
  • 滴鼻剂
  • 液体稳定性管瓶

升糖素市场规模(依最终用户和复合年增长率)(2025-2032 年)

  • 市场概览
  • 医院
  • 诊所
  • 药局
  • 网路药局
  • 居家照护环境

升糖素市场规模及复合年增长率(2025-2032)

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业市场定位(2024年)
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市场占有率分析(2024年)
  • 主要企业简介
    • 公司详情
    • 产品系列分析
    • 按部门分類的公司份额分析
    • 收益同比对比(2022-2024 年)

主要企业简介

  • Sun Pharmaceuticals Industries
  • Zealand Pharma
  • Biocon
  • KemPharm
  • Baxter International
  • Sandoz
  • Teva Pharmaceuticals Industries
  • Reddy's Laboratories
  • Mylan
  • Pfizer
  • Novo Nordisk
  • Xeris Pharmaceuticals
  • Eli Lilly and Company

结论和建议

简介目录
Product Code: SQMIG35H2367

Global Glucagon Market size was valued at USD 608.0 million in 2023 and is poised to grow from USD 644.48 million in 2024 to USD 1027.2 million by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global glucagon market is witnessing robust growth driven by the escalating prevalence of diabetes, increased adoption of emergency medical treatments, and heightened awareness surrounding severe hypoglycemia management. Demand for effective hypoglycemia interventions is surging as healthcare systems prioritize reliable treatment options. Advancements in emergency injectable solutions and nasal glucagon formulations are improving patient outcomes and enhancing market penetration. Efforts to educate healthcare professionals and patients on the urgency of addressing hypoglycemic episodes are further amplifying demand. Additionally, ongoing innovations in drug delivery systems and favorable government healthcare policies are fostering market expansion. However, challenges such as high treatment costs, insufficient awareness in lower-income regions, regulatory hurdles, and reliance on cold-chain logistics continue to impact market strategies and regional uptake.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucagon Market Segments Analysis

Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucagon Market

The rising prevalence of diabetes, particularly type 1 diabetes, worldwide is a significant factor propelling the growth of the glucagon market. Individuals living with insulin-dependent diabetes face the constant risk of severe hypoglycemia, which requires prompt intervention. This urgent healthcare necessity has led to a heightened demand for glucagon treatment options in various settings, including hospitals, clinics, and homecare environments. As the awareness of diabetes management and emergency response continues to expand, the need for effective glucagon solutions becomes more pronounced, further fueling the market's expansion and innovation in treatment methods.

Restraints in the Global Glucagon Market

The advanced glucagon delivery systems, including prefilled autoinjectors and nasal powders, present significant financial challenges due to their high development and production costs. This elevated pricing may hinder their acceptance, particularly in low- and middle-income countries, where affordability is a critical concern. Additionally, these expenses place a burden on healthcare systems and insurance providers, complicating the wider distribution and accessibility of innovative treatment options. As a result, the potential benefits of these modern glucagon formulations may not be realized on a broad scale, limiting the overall impact on patient care and health outcomes.

Market Trends of the Global Glucagon Market

The Global Glucagon market is experiencing notable growth driven by advancements in drug delivery technologies, such as liquid-stable formulations, nasal sprays, and autoinjectors. These innovations enhance the convenience and efficacy of glucagon administration, eliminating the need for reconstitution and improving shelf stability. This ease of use is particularly beneficial during emergencies, as it allows for prompt intervention in cases of severe hypoglycemia. As healthcare providers and patients increasingly demand more user-friendly solutions, the market is poised for expansion, reflecting a broader trend towards patient-centric approaches in diabetes management and emergency care.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies

Global Glucagon Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Hypoglycemia
  • Diabetic Ketoacidosis
  • Metabolic Disease Trials

Global Glucagon Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Intravenous
  • Subcutaneous
  • Intramuscular

Global Glucagon Market Size by Formulation & CAGR (2025-2032)

  • Market Overview
  • Injectable Kits
  • Liquid Stable Autoinjectors
  • Nasal Powder
  • Liquid Stable Vials

Global Glucagon Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Clinic
  • Drug Stores
  • Online Pharmacies
  • Home Care Setting

Global Glucagon Market Size & CAGR (2025-2032)

  • North America (Indication, Route of Administration, Formulation, End-User)
    • US
    • Canada
  • Europe (Indication, Route of Administration, Formulation, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Indication, Route of Administration, Formulation, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Indication, Route of Administration, Formulation, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Indication, Route of Administration, Formulation, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Sun Pharmaceuticals Industries
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zealand Pharma
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biocon
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KemPharm
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sandoz
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceuticals Industries
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Reddy's Laboratories
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Xeris Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations